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〉OS《やmicroenvironment╆やTAMsやexertやdiTerentialやactivitiesや inや theや tumourやdevelopmentや












Inや recentや years╇や thereや hasや beenや aや dramaticや increaseや inや theや importanceや givenや toや theや theoryや
thatや theや tissueやmicroenvironmentやparticipatesや inやdeterminingや theや｠boneやnicheをや inや theやpro-
gressionやofやboneやtumoursやandやinやestablishingやresistanceやprocessesやtoやconventionalやtherapies╆や
Originally╇や theやconceptやofや tumourやnicheやhasやemergedやbasedやonや theや｠seedやandやsoilや theoryをや
proposedやbyやStephanやPagetやatやtheやendやofやtheやnineteenthやcenturyや》ｱ, ｲ]. This tumour niche is 
deRnedやasやaや speciRcやmicroenvironmentやpromotingや theやemergenceやofや cancerや initiatingやcellsや
andや providingや allや theや factorsや requiredや forや theirや quiescence╇や proliferationや andや migration╆や
ﾃ 2017 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
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Therefore╇やtheやtumourやmicroenvironmentやisやcomposedやofやaやcomplex╇やinterconnectedやnetworkや
ofやprotagonists╇やincludingやsolubleやfactorsやsuchやasやcytokines╇やextracellularやmatrixやcompo-
nents╇や interactingやwithや Rbroblasts╇や endothelialや cells╇や immuneや cellsや andや variousや speciRcや
cellやtypesやdependingやonやtheやlocationやofやtheやcancerやcellsや〉e╆g╆やosteoblasts╇やosteoclastsやinやtheや
boneやtissueやorやpulmonaryやepitheliumやinやcaseやofや lungやmetastasis《╆やThisやcellularやdiversityや
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2. The immune niche in osteosarcoma































































boneや resorption╆やLGRｴや isや theや lastや receptorやofやRANKやrecentlyや identiRed╆やLGRｴやexpressedやatや






















inやtheやbody‒sやRrstやlineやofやdefenceやagainstやpathogensやandやparasitesや》39]. This system includes 






ofや theやtumourやmass╆やTheseやcellsやplayやaやpivotalやroleや inや tumourやbehaviourや illustratedやbyやtheや
signiRcantやlinkやbetweenやTAMやnumberやandやdensityやandやtheやprognosisや》ｱｸ, 43, 44『╆やWhereasや
TAMsやcanやexertやantiまtumourやactivities╇やtheやambiguousやroleやofやmacrophagesやinやtumourやpro-



























the in vivoやworkやdescribedや byやXiaoや etや al╆やwhoや showedや aや switchや inやmacrophageや subpopu-
lationsや inや aやmouseやmodelや ofや humanや osteosarcomaや fromやMｱまmacrophagesや duringや theや Rrstや
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improvementsやinやsurvivalやseenやoverやtheやpastやｳｰやyearsや》ｶｱ『╆やSeveralやreportsやhaveやunderlinedや
theやtherapeuticやvalueやofやusingやimmunotherapiesやorやimmunomodulatoryまbasedやtherapiesやforや
osteosarcomaや》ｱｵ, ｶｲ64『╆や Inやthisやcontext╇や theやnumberやofやnewやdrugsやactivatingやtheや immuneや
systemやhasやexplodedやinやtheや lastやｱｰやyearsやandやnumerousやphaseやIやandやIIやclinicalや trialsやareや inや
progressや inやosteosarcomaや 〉Figure 1《╆や Inや thisや chapter╇や theやmostや recentや therapeuticやdevelop-
mentsやtargetingやtheやregulationやofやTやlymphocytesやandやmacrophagesやwillやbeやexposed╆
2.3.1. T-cell therapies
Detectionや ofや speciRcや Tや lymphocyteや populationsや inや theや tumourや microenvironmentや andや inや
humanやtumourやtissuesやdeRnesやanやimmunoscoreやandやleadsやtoやpatientやstratiRcationやbasedやonや
thisや immunophenotyping╆や Theseや analysesや haveや identiRedや newや predictiveや biomarkersや andや
newやtherapeuticやtargets╇やwhichやhaveやstimulatedやtheやdevelopmentやofやimmunotherapiesや》65].
2.3.1.1. Disialoganglioside (GD2)
Monoclonalや antibodiesや targetedや againstや cellや surfaceや antigensや speciRcや toや tumourや cellsや haveや





》69ｷｱ『╆や Inや additionや toや theや healthyや tissues╇やGDｲやwasやdetectedや inや neuroblastomas╇やmelano-
mas╇や sarcomas╇や lungや andや centralや nervousや systemや tumours╇や inやwhichや aや variableやnumberや ofや
cancerやcellsやexpressやthisやantigenや》ｷｲ75『╆やBasedやonやthisやrelativeやrestrictedやdistribution╇やGDｲま






ingや theやuseやofや theseやmAbsや inやOSやareやunderwayや 》78『╆やCurrentや trialsや includeや theやGDｲmAbsや
humanizedｳFｸや〉NCTｰｱｴｱｹｸｳｴやandやNCTｰｱｶｶｲｸｰｴ《やandやhuｱｴ╆ｱｸKｳｲｲAや〉NCTｰｰｷｴｳｴｹｶ《や》ｶｱ].
2.3.1.2. Nivolumab
Nivolumabや isや anや immunomodulator╇や whichや actsや byや blockingや theや activationや ofや theや pro-
grammedやcellやdeathまｱや〉PDまｱ《やreceptor╇やinducedやbyやoneやofやitsやtwoやligandsや〉PDまLｱ《やonやactivatedや





inやOSやpatientsや thanや inや healthyや controlsや andや inやpatientsやwithやmetastasisや atや diagnosis╇や highや
tumourやstageやorやboneやfractureや》ｸｱ『╆やAやphaseやIのIIやtrialやwillやbeやconcludeやinやｲｰｱｶやonやrefractoryや






2.3.2. Immune and dendritic cell vaccine
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